Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial – Scientific American
|
Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial
Scientific American One company, Melbourne, Australia–based Mesoblast, is already in late-stage clinical trials, treating hundreds of chronic heart failure patients with stem cell precursors drawn from healthy donors’ hip bones. A randomized trial that includes a placebo … |
|
Oppenheimer Begins Coverage on Editas Medicine, Inc. (EDIT) With An Initial Rating Of “Perform”
First News 24 CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |
|
Oppenheimer Begins Coverage on Editas Medicine, Inc. (EDIT) With An Initial Rating Of “Perform”
First News 24 CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |
Technology Networks |
Synthetic Material to Support Stem Cells Developed
Technology Networks This week, a UW–Madison team reports in Nature Biomedical Engineering that they have jumped a major hurdle on the path toward wider use of stem cells. Using an automated screening test that they devised, William Murphy, a professor of biomedical … |
Pulmonary Hypertension News |
Mount Sinai, Theragene Form Partnership to Move Potential PH Gene Therapy to Clinical Development
Pulmonary Hypertension News New York’s Mount Sinai and Theragene Pharmaceuticals have joined efforts to move a novel investigational aerosol-delivered gene therapy to treat pulmonary hypertension (PH) into a clinical development program. The new therapy, if approved, will be the … |
Pulmonary Hypertension News |
Mount Sinai, Theragene Form Partnership to Move Potential PH Gene Therapy to Clinical Development
Pulmonary Hypertension News New York’s Mount Sinai and Theragene Pharmaceuticals have joined efforts to move a novel investigational aerosol-delivered gene therapy to treat pulmonary hypertension (PH) into a clinical development program. The new therapy, if approved, will be the … |
The Independent |
Leukaemia patient whose sister had UK visa refused for stem cell transplant dies
The Independent A woman whose sister was refused entry to the UK to donate her “perfect match” bone marrow has died from leukaemia. May Brown, 24, was told she needed an urgent stem cell transplant last year. But her sister, Martha Brown, was blocked from travelling … Woman who needed stem cell treatment dies after sister was … – MetroMetro May Brown: Visa battle transplant sister dies – BBC NewsBBC News Forever in our hearts: Young mum May Brown dies in hospital (From …Dorset Echo |